MindMed today announced the ethics committee approval of a Phase 1 clinical trial evaluating the acute effects of mescaline, with varying doses employed. The company hopes to start the trial at University Hospital Basel’s Liechti Lab later this month. Dr. Matthias Liechti commented, “This study will, we believe, provide the first modern research data on mescaline regarding dosing and mechanism of…
